Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
endocrine disorders
Biotech
AstraZeneca’s $800M bet undermined by immunogenicity in phase 3
Immunogenicity dragged on efficacy, causing the $800 million molecule’s response rate to fall short of the bar set by Ascendis Pharma’s Yorvipath.
Nick Paul Taylor
May 12, 2026 9:28am
Baynes ditches Merck for CMO role at Eikon—Chutes and Ladders
Mar 25, 2022 9:30am
Septerna launches with $100M and GPCR pioneer co-founder
Jan 27, 2022 7:00am
Novo-backed Amolyt Pharma snags $80M for endocrine pipeline
Sep 16, 2021 10:15am
MBX debuts with $35M to bankroll rare endocrine pipeline
Jul 27, 2020 8:00am
Spruce nets $88M to push rare disease drug into late-stage trial
Feb 20, 2020 9:55am
